| Literature DB >> 29849867 |
Paul K Waltz1, Benjamin Kautza1, Jason Luciano1, Mitch Dyer1, Donna Beer Stolz2,3, Patricia Loughran1,3, Matthew D Neal1,4, Jason L Sperry1,4, Matthew R Rosengart1,4, Brian S Zuckerbraun1,5.
Abstract
Hypoxia occurs as a part of multiple disease states, including hemorrhagic shock. Adaptive responses occur within the cell to limit the consequences of hypoxia. This includes changes in mitochondrial respiration, stress-induced cell signaling, and gene expression that is regulated by hypoxia inducible factor-1α (HIF-1α). Heme oxygenase-2 (HO-2) has been shown to be involved in oxygen sensing in several cell types. The purpose of these experiments was to test the hypothesis that HO-2 is a critical regulator of mitochondrial oxygen consumption and reactive oxygen species (ROS) production to influence hypoxia-adaptive responses such as HIF-1α protein levels and JNK signaling. Methods and Results. In vitro studies were performed in primary mouse hepatocytes. HO-2, but not HO-1, was expressed in mitochondria at baseline. Decreased oxygen consumption and increased mitochondrial ROS production in response to hypoxia were dependent upon HO-2 expression. HO-2 expression regulated HIF-1α and JNK signaling in a mitochondrial ROS-dependent manner. Furthermore, knockdown of HO-2 led to increased organ damage, systemic inflammation, tissue hypoxia, and shock in a murine model of hemorrhage and resuscitation. Conclusion. HO-2 signaling plays a role in hypoxic signaling and hemorrhagic shock. This pathway may be able to be harnessed for therapeutic effects.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29849867 PMCID: PMC5925001 DOI: 10.1155/2018/2021645
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1HO-2 is present within hepatocyte mitochondria under unstressed conditions. (a, b) Microscopy reveals localization of HO-2 within the mitochondria. Immunocytochemistry (a) demonstrates mitochondria (green; MitoTracker) and HO-2 (red) with areas of yellow representing colocalization. Immunoelectron microscopy demonstrates gold particle-labeled localization of HO-2 within hepatocyte mitochondria under normal cell culture conditions (b). (c, d) Western blot of mitochondrial fractions of untreated primary hepatocytes (c) and mouse liver (d) demonstrates HO-2 but not HO-1 expression protein levels under basal cell culture or without treatment. Mitochondrial cytochrome C oxidase subunit 4 (COX IV) is used as a mitochondrial loading control.
Figure 2HO-2 regulates oxidative phosphorylation in hypoxia. (a) Hepatocyte heme oxygenase activity is not influenced significantly by hypoxia and is diminished by tin protoporphyrin (SnPP) or HO-2 siRNA. ∗P < 0.05 compared to control siRNA in 21% O2. (b) Oxygen consumption is decreased in hepatocytes under hypoxic conditions, and this is reversed by nonspecific pharmacological inhibition of HO activity or knockdown of HO-2, but not HO-1. ∗P < 0.05 compared to vehicle controls in 21% O2; #P < 0.05 compared to vehicle controls in 1% O2. (c) Hypoxyprobe staining increases with decreased availability of intracellular oxygen. Hypoxyprobe staining increases under hypoxic conditions and increases further with knockdown of HO-2 (suggesting increased cellular hypoxia). (d) Mitochondrial ROS increases under hypoxia in hepatocytes as determined by relative MitoSOX fluorescence. This is reversed by knockdown of HO-2.
Figure 3Hypoxia-induced HIF-1α stabilization is dependent in part on HO-2 and mitochondrial ROS. (a) HIF-1α protein levels are increased in hepatocytes following 90 minutes of hypoxia. (b) Inhibition of HO activity with tin protoporphyrin (SnPP) limits hypoxia-induced increases in HIF-1α protein levels. (c–f) HO-2 siRNA decreases hypoxia induces HIF immunocytochemistry (d) and 1-α levels as determined by Western blotting (c) and luciferase-reporter assay (f). Furthermore, inhibition of mitochondrial ROS production by MitoTEMPO also decreases HIF-1α as determined by immunocytochemistry (e) and luciferase-reporter assay (f). ∗P < 0.05 compared to control siRNA 21% O2; #P < 0.05 compared to control siRNA 1% O2.
Figure 4Hypoxia-induced JNK phosphorylation is partially dependent on HO-2 and mitochondrial ROS production. (a) Phosphorylated JNK (p-JNK) is increased in hepatocytes following 90 minutes of hypoxia. (b) Inhibition of HO activity with tin protoporphyrin (SnPP) limits hypoxia-induced increases in phosphorylation of JNK. (c) HO-2 siRNA limits phosphorylation of JNK during a one-hour time course of hypoxia treatment. (d) Treatment with MitoTEMPO to limit mitochondrial ROS generation decreases hypoxia-induced JNK phosphorylation at a 60-minute time point.
Figure 5Inhibition of HO-2 exacerbates injury and inflammation in a murine hemorrhagic shock model. (a, b) Knockdown of HO-2 exacerbates hemorrhagic shock-induced serum TNF-α (275 ± 56 control siRNA versus 387 ± 67 HO-2 siRNA) and IL-6 (621 ± 87 control siRNA versus 903 ± 91 HO-2 siRNA). Units are pg/mL; ∗P < 0.05 compared to sham mice and #P < 0.05 compared to shock control siRNA mice. N = 6 mice per group. (c, d) Liver injury and hypoxia were worse in the setting of knockdown of HO-2. Serum ALT increased from 225 ± 59 to 573 ± 102 IU/mL; n = 6 mice per group (c). Hemorrhagic shock also resulted in increased tissue hypoxia as demonstrated by staining for the nitroimidazole EF5, which was also increased by HO-2 siRNA pretreatment (d). (e) Knockdown of HO-2 or nonspecific inhibition of HO activity is associated with earlier decompensation in severe hemorrhagic shock (MAP 20 mmHg). N = 6 mice per group. (f) Arterial pH 30 minutes into severe hemorrhagic shock is decreased compared to control mice (7.32 ± 0.05 versus 7.18 ± 0.08 in shock control siRNA; ∗P < 0.05). This clinical shock parameter is further decreased in HO-2 siRNA-treated mice (7.03 ± 0.06; #P < 0.05 versus shock control siRNA mice). N = 8 mice per group.